https://www.selleckchem.com/pr....oducts/eflornithine-
88, 95% CI 5.52-151.18; p0.0001) in regard to hepatic recurrence on univariate analysis. Increased hepatic recurrence correlated with decreased 3-year OS and DFS rates of 30.6% versus 50.3% (OR 0.44, 95% CI 0.20-0.94; p=0.032) and 13.6% versus 36.9% (OR 0.27, 95% CI 0.08-0.97; p=0.035). Systemic therapy limited the effects of aRHA. aRHA was associated with inferior survival outcomes due to the significantly increased risk of hepatic metastatic disease with aberrant anatomy. This study provides important pr
Like
Comment
Share
